Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results [Yahoo! Finance]
Palisade Bio, Inc. (PALI)
Company Research
Source: Yahoo! Finance
Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for its treatment of fibrostenotic Crohn's disease (FSCD). The company is targeting to present the topline results of its Phase 1b study of PALI-2108 in the first quarter of 2026, with the Investigational New Drug submission expected in the first half of next year. The first phase enrolled approximately 6 to 12 patients with FSCD, and was designed to evaluate the efficacy of PALI-2108 over a 14-day treatment period. Results aside, the rally in Palisade Bio Inc. (NASDAQ:PALI) can also be attributed to some window-dressing activities—a practice among institutional investors where they tweak their portfolios before reporting periods, typically done quarterly and annually, by loading up on well-performing stocks and trimming those that underperform, to perform a stronger portfolio for clie
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease ConferencesGlobeNewswire
- Palisade Bio (NASDAQ:PALI) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.MarketBeat
- Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108 [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108GlobeNewswire
- Palisade Bio (NASDAQ:PALI) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=PALI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</MarketBeat
PALI
Sec Filings
- 1/13/26 - Form 4
- 12/8/25 - Form SCHEDULE
- 12/4/25 - Form 8-K
- PALI's page on the SEC website